News

Keyword Search
 
DateTitle 
08/14/17PRA Health Sciences Announces Appointment of New Director
RALEIGH, N.C., Aug. 14, 2017 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) today announced the appointment of Alexander G. Dickinson to the Board of Directors of the Company. “We are pleased that Alex will be joining our Board of Directors.  Alex’s background in technology and informatics will be a tremendous value to us as we seek to leverage our recent acquisitions of Parallel6 and Symphony Health as part of our initiatives to leverage technology and data to shape the future... 
Printer Friendly Version
08/09/17PRA Health Sciences, Inc. Announces Pricing of Secondary Offering of 10,000,000 Shares of Common Stock
RALEIGH, N.C., Aug. 09, 2017 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (the “Company”) (NASDAQ:PRAH) today announced the pricing of the previously announced secondary offering of shares of its common stock.  Certain of the Company’s stockholders, including an affiliate of, or a fund sponsored by, Kohlberg Kravis Roberts & Co. (the “Selling Stockholders”), have agreed to sell an aggregate of 10,000,000 shares of the Company’s common stock in an underwritten public offering. The shares w... 
Printer Friendly Version
08/08/17PRA Health Sciences, Inc. Announces Secondary Offering of 10,000,000 Shares of Common Stock
RALEIGH, N.C., Aug. 08, 2017 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (the “Company”) (NASDAQ:PRAH) today announced that certain of its stockholders, including an affiliate of, or a fund sponsored by, Kohlberg Kravis Roberts & Co. (the “Selling Stockholders”), intend to offer for sale in an underwritten secondary offering 10,000,000 shares of common stock of the Company pursuant to the Company’s shelf registration statement filed with the Securities and Exchange Commission. The Sellin... 
Printer Friendly Version
08/07/17PRA Health Sciences, Inc. Reports Second Quarter 2017 Results and Updates Full Year 2017 Guidance
Net new business of $603.2 million; Net book-to-bill of 1.32 $457.9 million of service revenue; 16.2% growth at actual foreign exchange rates and 16.5% constant currency growth   GAAP Net Income per diluted share was $0.45 and GAAP Net Income was $29.5 million   Adjusted Net Income per diluted share was $0.79 per share and Adjusted Net Income was $51.7 million   Updating full year 2017 service revenue guidance to between $1.825 billion and $1.855 billion, GAAP net income per ... 
Printer Friendly Version
08/07/17PRA Health Sciences to acquire Symphony Health Solutions, a leading provider of integrated health data and analytics delivered as cloud-based solutions
Enters into definitive agreement to acquire Symphony Health Solutions for upfront cash payment of $ 530 million Strengthens commitment to patient care through enhanced real world evidence based solutions Empowers vision for a more agile, flexible, and adaptive way of conducting clinical research Transaction expected to be immediately accretive to PRA Health Sciences’ adjusted net income per diluted share RALEIGH, N.C., Aug. 07, 2017 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. ... 
Printer Friendly Version
07/25/17PRA Health Sciences to Report 2nd Quarter 2017 Earnings
RALEIGH, N.C., July 25, 2017 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its second quarter results after the market closes on Monday, August 7, 2017. The Company will also host a conference call on Tuesday, August 8 at 9:00 a.m. (ET) to discuss the results with members of the investment community. To participate via telephone, investors and analysts should dial (877) 930-8062 within the United States or (253) 336-7647 outside the United States approximately 10 ... 
Printer Friendly Version
06/19/17PRA Health Sciences and Jumo Announce Partnership
RALEIGH, N.C., June 19, 2017 (GLOBE NEWSWIRE) -- As part of its new Center for Pediatric Clinical Development initiative, PRA Health Sciences is pleased to announce its partnership with Jumo. Jumo is an award-winning provider of educational health care information and resources for children, families, and caregivers. “We are excited about this partnership,” said Mark Sorrentino, Vice President, The Center for Pediatric Clinical Development. “When it comes to pediatric clinical trials, we kn... 
Printer Friendly Version
05/22/17PRA Health Sciences Named International Clinical Research Company of the Year
RALEIGH, N.C., May 22, 2017 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc., (PRA) (NASDAQ:PRAH) is pleased to announce that for the fourth consecutive year it was recognized as the International Clinical Research Company of the Year. PRA received the award at a PharmaTimes ceremony in London. This award follows PRA’s recent recognition as Clinical Research Company of the Year in the PharmaTimes Americas competition. ... 
Printer Friendly Version
05/04/17PRA Health Sciences Announces The Center for Pediatric Clinical Development
RALEIGH, N.C, May 04, 2017 (GLOBE NEWSWIRE) -- It is a little known fact that 70% of medicines given to children have been studied only in adults. As a result, most drugs used to treat diseases in children are used off-label. While there are pediatric clinical trial regulations in place, testing drugs in children continues to present considerable scientific, clinical, ethical and logistical challenges. In an effort to confront these challenges, PRA Health Sciences (NASDAQ:PRAH) is pleased to a... 
Printer Friendly Version
05/02/17PRA Health Sciences Named Clinical Research Company of the Year
RALEIGH, N.C., May 02, 2017 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (PRA) (NASDAQ:PRAH) is pleased to announce that it was once again recognized as the Clinical Research Company of the Year. PRA received the award at the PharmaTimes Clinical Researcher of the Year Americas ceremony in Seattle, Washington. This is the fifth consecutive year that PRA has received this prestigious recognition. ... 
Printer Friendly Version
04/25/17PRA Health Sciences, Inc. Reports First Quarter 2017 Results
Net new business of $564.8 million in the first quarter; Net book-to-bill of 1.32 $427.1 million of service revenue in the first quarter; 14.7% growth at actual foreign exchange rates and 15.1% constant currency growth compared to the first quarter of 2016 First quarter GAAP Net Income per diluted share was $0.39 and GAAP Net Income was $25.2 million First quarter Adjusted Net Income per diluted share was $0.62 per share and Adjusted Net Income was $40.4 million Reaffirming full yea... 
Printer Friendly Version
04/17/17PRA Health Sciences to Report First Quarter 2017 Earnings
RALEIGH, N.C., April 17, 2017 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its first quarter 2017 results after the market closes on Tuesday, April 25, 2017. The Company will also host a conference call on Wednesday, April 26, 2017 at 9:00 a.m. (ET) to discuss the results and guidance with members of the investment community. To participate via telephone, investors and analysts should dial (877) 930-8062 within the United States or (253) 336-7647 outside the Unit... 
Printer Friendly Version
03/27/17PRA Health Sciences Named Top Workplace in Philadelphia
RALEIGH, N.C., March 27, 2017 (GLOBE NEWSWIRE) -- For the second year in a row, PRA Health Sciences (PRA) (NASDAQ:PRAH), a leading global contract research organization, has been awarded a Top Workplaces honor by Philly.com. “We are honored to once again receive this recognition,” said Tami Klerr, Executive Vice President, Business Development. “We know that our employees are the foundation of our success and it is because of their dedication and hard work that we are leaders in our industr... 
Printer Friendly Version
02/22/17PRA Health Sciences, Inc. Reports Fourth Quarter and Full Year 2016 Results and Provides Q1 and Full Year 2017 Guidance
Net new business of $587.3 million in the fourth quarter; Net book-to-bill of 1.42   $413.6 million of service revenue in the fourth quarter; 14.2% growth at actual foreign exchange rates and 14.6% constant currency growth compared to the fourth quarter of 2015   Fourth quarter GAAP Net Income per diluted share was $0.22 and GAAP Net Income was $14.0 million   Fourth quarter Adjusted Net Income per diluted share was $0.71 per share and Adjusted Net Income was $45.9 million RALEIG... 
Printer Friendly Version
02/15/17PRA Health Sciences and Takeda Partnership Expands to Japan
Osaka, Japan, February 15, 2017 and Raleigh, N.C., February 15, 2017 – PRA Health Sciences, Inc. (NASDAQ: PRAH,“PRA”) and Takeda Pharmaceutical Company Limited (TSE: 4502, “Takeda”) announced today that they have agreed to a new partnership to expand their global relationship initially disclosed in September 2016 to include Japan.Takeda and PRA will establish a joint venture, each holding 50% of the share respectively, to provide clinical trial delivery and pharmacovigil... 
Printer Friendly Version
02/02/17PRA Health Sciences to Report Fourth Quarter 2016 Earnings and Issue 2017 Guidance
RALEIGH, N.C., Feb. 02, 2017 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its fourth quarter and year end 2016 results and issue 2017 guidance after the market closes on Wednesday, February 22, 2017. The Company will also host a conference call on Thursday, February 23, 2017 at 9:00 a.m. (ET) to discuss the results and guidance with members of the investment community. To participate via telephone, investors and analysts should dial (877) 930-8062 within the Unit... 
Printer Friendly Version
11/10/16PRA Health Sciences, Inc. Announces Secondary Offering of 7,500,000 Shares of Common Stock
RALEIGH, N.C., Nov. 10, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (the “Company”) (NASDAQ:PRAH) today announced that one of its stockholders, consisting of an affiliate of, or a fund sponsored by, Kohlberg Kravis Roberts & Co. (the “Selling Stockholder”), intends to offer for sale in an underwritten secondary offering 7,500,000 shares of common stock of the Company pursuant to the Company’s shelf registration statement filed with the Securities and Exchange Commission. The Selling... 
Printer Friendly Version
11/02/16PRA Health Sciences, Inc. Reports Third Quarter 2016 Results and Updates 2016 Guidance
$399.8 million of service revenue in the third quarter; 16.0% constant currency growth compared to the third quarter of 2015   Third quarter GAAP Net Income per diluted share increased 32.4% to $0.49 per diluted share and GAAP Net Income increased 32.9% to $31.4 million compared to the third quarter of 2015   $74.7 million of Adjusted EBITDA in the third quarter; 12.2% growth compared to the third quarter of 2015   Third quarter Adjusted Net Income per diluted share increased 23.1% ... 
Printer Friendly Version
10/10/16PRA Health Sciences to Report Third Quarter 2016 Earnings
RALEIGH, N.C., Oct. 10, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its third quarter 2016 results after the market closes on Wednesday, November 2. The Company will also host a conference call on Thursday, November 3 at 9:00 a.m. (ET) to discuss the results with members of the investment community. To participate via telephone, investors and analysts should dial (877) 930-8062 within the United States or (253) 336-7647 outside the United States approximate... 
Printer Friendly Version
09/12/16Takeda and PRA Health Sciences Announce Transformational Clinical Development and Marketed Product Partnership
Agreement Supports Accelerated, More Efficient Clinical Trial Strategy and Operations OSAKA, Japan & RALEIGH, N.C.--(BUSINESS WIRE)--PRA Health Sciences, Inc. (NASDAQ: PRAH) and Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that the companies have entered into a new partnership agreement under which PRA Health Sciences (PRA) will serve as Takeda's primary strategic partner to deliver on the company's pipeline and marketed products clinical devel... 
Printer Friendly Version
07/28/16PRA Health Sciences, Inc. Reports Second Quarter 2016 Results
$394.2 million of service revenue in the second quarter; 17.3% constant currency growth compared to the second quarter of 2015 Second quarter GAAP Net Income per diluted share increased 200.0% to $0.60 per diluted share and GAAP Net Income increased 211.5% to $38.7 million compared to the second quarter of 2015 $73.3 million of Adjusted EBITDA in the second quarter; 19.6% growth compared to the second quarter of 2015 Second quarter Adjusted Net Income per diluted share increased 34.0% t... 
Printer Friendly Version
07/18/16PRA Health Sciences to Report Second Quarter 2016 Earnings
RALEIGH, N.C., July 18, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its second quarter 2016 results after the market closes on Thursday, July 28. The Company will also host a conference call on Friday, July 29 at 9:00 a.m. (ET) to discuss the results with members of the investment community. To participate via telephone, investors and analysts should dial (877) 930-8062 within the United States or (253) 336-7647 outside the United States approximately 10 mi... 
Printer Friendly Version
05/17/16PRA Health Sciences Named International Clinical Research Company of the Year
RALEIGH, N.C., May 17, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc., (PRA) (NASDAQ:PRAH) is pleased to announce that for the third consecutive year it was recognized as the Clinical Research Company of the Year. PRA received the award at the PharmaTimes International Clinical Researcher of the Year ceremony in London. This award follows PRA’s recent recognition as Clinical Research Company of the Year in the PharmaTimes Americas competition where PRA captured six individual awards, inclu... 
Printer Friendly Version
05/02/16PRA Health Sciences, Inc. Announces Secondary Offering of 5,000,000 Shares of Common Stock
RALEIGH, N.C., May 02, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (the “Company”) (NASDAQ:PRAH) today announced that certain of its stockholders (the “Selling Stockholders”), intend to offer for sale in an underwritten secondary offering 5,000,000 shares of common stock of the Company pursuant to the Company’s shelf registration statement filed with the Securities and Exchange Commission. The Selling Stockholders will receive all of the proceeds from this offering. No shares are being ... 
Printer Friendly Version
04/27/16PRA Health Sciences, Inc. Reports First Quarter 2016 Results and Updates 2016 Guidance
$372.3 million of service revenue in the first quarter; 13.0% constant currency growth compared to the first quarter of 2015   First quarter GAAP Net Loss of $16.0 million or $0.27 per diluted share, which includes $28.9 million of one-time transaction-related costs and a $21.5 million loss from the completion of our Senior Note tender offer   $67.4 million of Adjusted EBITDA in the first quarter; 20.8% growth compared to the first quarter of 2015   First quarter Adjusted Net Income ... 
Printer Friendly Version
04/18/16PRA Health Sciences Named Clinical Research Company of the Year
RALEIGH, N.C., April 18, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc., (PRA) (NASDAQ:PRAH) is pleased to announce it was once again recognized as the Best Clinical Research Company of the Year. PRA received the award at the PharmaTimes Clinical Researcher of the Year Americas ceremony in Atlanta, Georgia. This is the second year in a row that PRA has received this prestigious recognition. In 2015 PRA was also named the Best International Clinical Company of the Year. ... 
Printer Friendly Version
04/15/16PRA Health Sciences to Report First Quarter 2016 Earnings
RALEIGH, N.C., April 15, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its first quarter 2016 results after the market closes on Wednesday, April 27, 2016. The Company will also host a conference call on Thursday, April 28, 2016 at 9:00 a.m. (ET) to discuss the results with members of the investment community. To participate via telephone, investors and analysts should dial (877) 930-8062 within the United States or (253) 336-7647 outside the United States ap... 
Printer Friendly Version
03/31/16PRA Health Sciences Receives Recognition from Vaccine Industry Excellence (ViE)
RALEIGH, N.C., March 31, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences (PRA) (NASDAQ:PRAH), is pleased to announce that it received a “Highly Commended” designation by Vaccine Industry Excellence (ViE) for Best Contract Research Organization. PRA was originally named a finalist in the category based on industry nominations. Finalists submitted a detailed questionnaire about their vaccine capabilities which was then blinded, reviewed, and rated by a panel of judges. “This is a great honor,” s... 
Printer Friendly Version
03/21/16PRA Health Sciences Named Top Workplace in Philadelphia
RALEIGH, N.C., March 21, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences (PRA) (NASDAQ:PRAH), a leading global contract research organization, is pleased to announce that it has been awarded a 2016 Top Workplaces honor by Philly.com. The Top Workplaces recognition is based solely on the results of an employee feedback survey administered by WorkplaceDynamics, LLC, a leading research firm that specializes in organizational health and workplace improvement. “We are honored to receive this recogn... 
Printer Friendly Version
03/17/16PRA Holdings, Inc. Announces Completion of Cash Tender Offer for its 9.500% Senior Notes Due 2023
RALEIGH, N.C., March 17, 2016 (GLOBE NEWSWIRE) -- PRA Holdings, Inc. (“PRA Holdings”), a wholly-owned subsidiary of PRA Health Sciences, Inc. (“PRA”) (NASDAQ:PRAH), today announced that the previously announced cash tender offer for up to $133,559,000 aggregate principal amount of its outstanding 9.500% Senior Notes due 2023 (referred to below as the “notes”) expired at 11:59 p.m., New York City time, on March 16, 2016 (the “Expiration Time”). At the Expiration Time, $133,559,000 principal ... 
Printer Friendly Version
03/03/16PRA Holdings, Inc. Announces Preliminary Results of Cash Tender Offer and Increase in Maximum Tender Amount of Its 9.500% Senior Notes Due 2023
RALEIGH, N.C., March 03, 2016 (GLOBE NEWSWIRE) -- PRA Holdings, Inc. (“PRA Holdings”), a wholly-owned subsidiary of PRA Health Sciences, Inc. (“PRA”) (NASDAQ:PRAH), today announced the preliminary results of its previously announced cash tender offer for up to $75 million aggregate principal amount (the “Maximum Tender Amount”) of its 9.500% Senior Notes due 2023 (referred to below as the “notes”).  Approximately $225 million in aggregate principal amount of the notes is currently outstanding.... 
Printer Friendly Version
03/02/16PRA Health Sciences, Inc. Announces Secondary Offering of Five Million Shares of Common Stock
RALEIGH, N.C., March 02, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (the “Company”) (NASDAQ:PRAH) today announced that certain of its stockholders (the “Selling Stockholders”), intend to offer for sale in an underwritten secondary offering five million shares of common stock of the Company pursuant to the Company’s shelf registration statement filed with the Securities and Exchange Commission. The Selling Stockholders will receive all of the proceeds from this offering. No shares are b... 
Printer Friendly Version
02/24/16PRA Health Sciences, Inc. Reports Fourth Quarter and Full Year 2015 Results and Provides 2016 Guidance
$362.3 million of service revenue in the fourth quarter; 15.1% constant currency growth compared to the fourth quarter of 2014 Fourth quarter GAAP Net Income was $28.5 million or $0.45 per diluted share $67.9 million of Adjusted EBITDA in the fourth quarter; 34.2% growth compared to the fourth quarter of 2014 Fourth quarter Adjusted Net Income per diluted share increased 68.6% to $0.59 per share and Adjusted Net Income increased 101.2% to $37.5 million compared to the fourth... 
Printer Friendly Version
02/18/16PRA Holdings, Inc. Announces Cash Tender Offer for up to $75 Million Aggregate Principal Amount of its 9.500% Senior Notes due 2023
RALEIGH N.C., Feb. 18, 2016 (GLOBE NEWSWIRE) -- PRA Holdings, Inc. (“PRA Holdings”), a wholly-owned subsidiary of PRA Health Sciences, Inc. (“PRA”) (NASDAQ: PRAH), today announced that it has commenced a cash tender offer for  up to $75 million aggregate principal amount (the “Maximum Tender Amount”) of its 9.500% Senior Notes due 2023 (referred to below as the “notes”). Approximately $225 million in aggregate principal amount of the notes is currently outstanding. The tender offer is being... 
Printer Friendly Version
02/04/16PRA Health Sciences to Report Fourth Quarter 2015 Earnings
RALEIGH, N.C., Feb. 04, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its fourth quarter and year end 2015 results after the market closes on Wednesday, February 24, 2016. The Company will also host a conference call on Thursday, February 25, 2016 at 9:00 a.m. (ET) to discuss the results with members of the investment community. To participate via telephone, investors and analysts should dial (877) 930-8062 within the United States or (253) 336-7647 outside t... 
Printer Friendly Version
12/07/15WuXi PharmaTech and PRA Health Sciences Restructure Relationship in China
SHANGHAI, China and RALEIGH, N.C., Dec. 07, 2015 (GLOBE NEWSWIRE) -- WuXi PharmaTech (Cayman) Inc. (NYSE:WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, and PRA Health Sciences, Inc. (NASDAQ:PRAH), a leading global clinical contract research organization, today announced a restructuring of their relationship for the delivery of clinical trial management services in China, Macau and Hong Kong... 
Printer Friendly Version
11/02/15PRA Health Sciences, Inc. Reports Third Quarter 2015 Results and Provides Updated 2015 Guidance
$345.1 million of service revenue in the third quarter; 12% constant currency growth compared to the third quarter of 2014 $66.6 million of Adjusted EBITDA in the third quarter; 42% growth compared to the third quarter of 2014  Third quarter Adjusted Net Income per share increased 53% to $0.52 per share and Adjusted Net Income increased 134% to $33.2 million compared to the third quarter of 2014  Third quarter GAAP Net Income was $23.7 million or $0.37 per diluted share  Upda... 
Printer Friendly Version
10/26/15PRA Health Sciences Opens New Bioanalytical Laboratory in the Netherlands
RALEIGH, N.C., Oct. 26, 2015 (GLOBE NEWSWIRE) -- PRA Health Sciences (PRA) (NASDAQ:PRAH) is pleased to announce the opening of its brand new, state-of-the-art Bioanalytical Laboratory in Assen, the Netherlands. The 33,000 square foot facility provides 25 percent more space than PRA’s previous lab, includes investments in the newest small and large molecule equipment, and allows for optimal bioanalytical process efficiencies. The new laboratory is also located close to PRA’s Phase I clinics in ... 
Printer Friendly Version
10/16/15PRA Health Sciences to Report Third Quarter 2015 Results
RALEIGH, N.C., Oct. 16, 2015 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its third quarter 2015 results after the market closes on Monday, November 2, 2015. The Company will also host a conference call on Tuesday, November 3, 2015 at 9:00 a.m. (ET) to discuss the results with members of the investment community. To participate via telephone, investors and analysts should dial (877) 930-8062 within the United States or (253) 336-7647 outside the United States appro... 
Printer Friendly Version
10/13/15PRA Health Sciences Announces Appointment of New Director
RALEIGH, N.C., Oct. 13, 2015 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) today announced the appointment of Linda S. Grais, M.D. to the Board of Directors of the Company. As a member of the Board of Directors, Dr. Grais will also serve on the Audit Committee. “We are delighted that Linda will be joining our Board of Directors. With her extensive experience in the healthcare field as a physician, attorney, and biotechnology entrepreneur, Dr. Grais will bring a valuable perspe... 
Printer Friendly Version
09/29/15PRA Health Sciences Collaborates With AMR to Accelerate Vaccine Development
RALEIGH, N.C., Sept. 29, 2015 (GLOBE NEWSWIRE) -- In an effort to accelerate new vaccines to market, PRA Health Sciences (PRA) (NASDAQ:PRAH) is pleased to announce its collaboration with Alliance for Multispecialty Research (AMR). This partnership paves the way for a smarter approach to vaccine studies that will allow studies to run more efficiently and effectively. "This is an ideal collaboration," said Frank Hijek, PRA Senior Vice President, Strategic Drug Development. "It combines the exp... 
Printer Friendly Version
09/10/15PRA Health Sciences Looks to Expand Workforce in Pennsylvania
RALEIGH, N.C., Sept. 10, 2015 (GLOBE NEWSWIRE) -- PRA Health Sciences (PRA) (NASDAQ:PRAH) a leading global contract research organization, is expanding its presence in Pennsylvania. Employees recently relocated from the company's Horsham and Fort Washington facilities to PRA's new modern Class A+ office space in Blue Bell, now the company's largest office worldwide. PRA currently has more than one thousand employees in Pennsylvania and is looking to add additional staff. "We are delighted to... 
Printer Friendly Version
07/27/15PRA Health Sciences, Inc. Reports Second Quarter 2015 Results and Provides Updated Guidance for 2015
$336.5 million of service revenue in the second quarter; 12% constant currency growth compared to the second quarter of 2014 $61.3 million of Adjusted EBITDA in the second quarter; 35% growth compared to the second quarter of 2014 Second quarter Adjusted Net Income per share increased 37% to $0.47 per share and Adjusted Net Income increased 112% to $29.7 million compared to the second quarter of 2014 Second quarter GAAP Net Income was $12.4 million or $0.20 pe... 
Printer Friendly Version
07/20/15PRA Health Sciences Launches New Initiative to Bolster Workforce
RALEIGH, N.C., July 20, 2015 (GLOBE NEWSWIRE) -- PRA Health Sciences (PRA) (NASDAQ:PRAH) is looking to hire new talent. To help attract potential employees from around the world, PRA, a leading global contract research organization (CRO), is launching a new Candidate Experience initiative. Just as PRA is finding innovative ways to improve the clinical development process, it is also developing creative strategies to meet the ever-growing need to identify highly skilled clinical research employee... 
Printer Friendly Version
07/16/15PRA Health Sciences Announces Time Change for Second Quarter 2015 Financial Results Conference Call
RALEIGH, N.C., July 16, 2015 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) announced today that it has adjusted the start time for its second quarter 2015 financial results conference call on Tuesday, July 28, 2015. The call will now begin at 8:00 a.m. (ET). To participate via telephone, investors and analysts should dial (877) 930-8062 within the United States or (253) 336-7647 outside the United States approximately 10 minutes prior to the call start time. The conference ID f... 
Printer Friendly Version
07/15/15PRA Health Sciences to Report Second Quarter 2015 Results
RALEIGH, N.C., July 15, 2015 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its second quarter 2015 results after the market closes on Monday, July 27, 2015. The Company will also host a conference call and webcast on Tuesday, July 28, 2015 at 9:00 a.m. (ET) to discuss the results with members of the investment community. To participate via telephone, investors and analysts should dial (877) 930-8062 within the United States or (253) 336-7647 outside the United Stat... 
Printer Friendly Version
06/15/15PRA Continues the Transformation of Clinical Trials With Predictivv(TM)
RALEIGH, N.C., June 15, 2015 (GLOBE NEWSWIRE) -- PRA Health Sciences (Nasdaq:PRAH), a leading global contract research organization, today announced its new Predictivv™ platform, the beginning of an entirely new approach on the role technology will play in the future of clinical development. The Predictivv™ platform will be a fully integrated solution for designing, planning and optimizing the management of global clinical studies. Designed around a unified platform that harmonizes data, process... 
Printer Friendly Version
06/08/15PRA Named Clinical Company of the Year
RALEIGH, N.C., June 8, 2015 (GLOBE NEWSWIRE) -- PRA Health Sciences (PRA) is pleased to announce that it was once again recognized as the Best Clinical Company of the Year. PRA received the award at the PharmaTimes Clinical Researcher of the Year Americas ceremony in Cary, North Carolina. This award follows PRA's recognition as the Best International Clinical Company of the Year which was announced earlier this year in London. In addition to the recognition received by the company, several P... 
Printer Friendly Version
05/12/15PRA Sponsors Russian Regional Quality Assurance Forum
RALEIGH, N.C., May 12, 2015 (GLOBE NEWSWIRE) -- PRA Health Sciences (PRA) is pleased to sponsor the first meeting of Quality Assurance (QA) experts in Russia. The Russian Regional Research Quality Association (RQA) Forum will facilitate knowledge sharing and the exchange of ideas and opinions in the QA community. "We are very excited about this opportunity," said Stanislav Gneushev, Senior Director, QA, PRA Health Sciences and the Chair of the RQA Forum. "This forum is a chance to establish ... 
Printer Friendly Version
05/06/15PRA Health Sciences, Inc. Reports First Quarter 2015 Results and Provides Updated Guidance for 2015
$332.0 million of service revenue in the first quarter; 10% constant currency service revenue growth compared to the first quarter of 2014 $55.7 million of Adjusted EBITDA in the first quarter; 40% growth compared to the first quarter of 2014 First quarter Adjusted Net Income per share increased 86% to $0.41 per share and Adjusted Net Income increased 190% to $25.8 million compared to the first quarter of 2014 First quarter GAAP Net Income was $17.2 million or $0.27 per share ... 
Printer Friendly Version
04/27/15PRA is Named International Clinical Company of the Year
RALEIGH, N.C., April 27, 2015 (GLOBE NEWSWIRE) -- PRA Health Sciences (PRA) is pleased to announce that it was named Clinical Company of the Year at the International Clinical Researcher of the Year award ceremony in London. This is the second year in a row that PRA has won this prestigious award. PRA also swept the Clinical Team of the Year category. PRA winners include: Clinical Research Associate: Charlotte Holmes Project Manager: Silvia Casellas Clinical Team Leader: Emma... 
Printer Friendly Version
04/17/15PRA Health Sciences to Report First Quarter 2015 Results
RALEIGH, N.C., April 17, 2015 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (Nasdaq:PRAH) will release its first quarter 2015 results after the market closes on Wednesday, May 6, 2015. The Company will also host a conference call and webcast on Thursday, May 7, 2015 at 9:00 a.m. (ET) to discuss the results with members of the investment community. To participate via telephone, investors and analysts should dial (877) 930-8062 within the United States or (253) 336-7647 outside the United Stat... 
Printer Friendly Version
04/17/15PRA Health Sciences to Add New Jobs in Swansea
(Thomson Reuters ONE via COMTEX) --RALEIGH, N.C., April 17, 2015 (GLOBE NEWSWIRE) -- PRA Health Sciences (PRA), a leading global clinical research organization, is expanding its business in Swansea with the creation of 87 new jobs. The expansion will be supported by £990,060 of business finance from the Welsh Government enabling PRA to grow its local workforce to 280 by December 2017. This growth follows a recent expansion that saw over 100 new jobs created in PRA's Swansea location, doubling... 
Printer Friendly Version
03/30/15PRA Health Sciences Expands Global Phase I Patient Strategy
RALEIGH, N.C., March 30, 2015 (GLOBE NEWSWIRE) -- PRA Health Sciences (PRA) is enhancing its global Phase I patient strategy and increasing its clinical footprint with the expansion of its Early Development Services (EDS). These initiatives are being undertaken in response to market demand to include patients as early as possible in early phase clinical trial development and include: Opening an 11,000 square foot outpatient facility at PRA's Salt Lake City, Utah site, focusing on psychia... 
Printer Friendly Version
02/18/15PRA Health Sciences, Inc. Reports 4th Quarter and Full Year 2014 Results and 2015 Guidance
$323.8 million of service revenue in the fourth quarter; 8% consolidated service revenue growth compared to the fourth quarter of 2013   $50.6 million of Adjusted EBITDA in the fourth quarter; 44% growth compared to the fourth quarter of 2013   Fourth quarter Adjusted Net Income per share increased 35% to $0.35 per share and Adjusted Net Income increased 80% to $18.6 million compared to the fourth quarter of 2013   Fourth quarter GAAP Net Loss per share was $0.45... 
Printer Friendly Version
02/09/15PRA Health Sciences Announces Appointment of New Director
RALEIGH, N.C., Feb. 9, 2015 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (Nasdaq:PRAH) today announced the appointment of Matthew P. Young to the Board of Directors of the Company. As a member of the Board of Directors, Mr. Young will also serve on the Audit Committee. "We are delighted that Matthew will be joining our Board of Directors. Not only does he bring significant expertise in all aspects of corporate finance, but much of his career has been spent in the healthcare and life science... 
Printer Friendly Version
02/04/15PRA Health Sciences to Report Fourth Quarter 2014 Earnings
RALEIGH, N.C., Feb. 4, 2015 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (Nasdaq:PRAH) will release its fourth quarter and year end 2014 results after the market closes on Wednesday, February 18, 2015. The Company will also host a conference call and webcast on Thursday, February 19, 2015 at 9:00 a.m. (ET) to discuss the results with members of the investment community. To participate via telephone, investors and analysts should dial (877) 930-8062 within the United States or (253) 336-7647... 
Printer Friendly Version
12/12/14PRA Health Sciences, Inc. Announces Pricing of its Initial Public Offering
12 November 2014, Raleigh, N.C. – PRA Health Sciences, Inc. (“PRA”), a leading global contract research organization, today announced the pricing of its initial public offering of 16,976,744 shares of its common stock at $18.00 per share. The shares are expected to begin trading on the Nasdaq Global Select Market on November 13, 2014 under the ticker symbol “PRAH,” and the offering is expected to close on November 18, 2014, subject to customary closing conditions. PRA has granted the underwriter... 
Printer Friendly Version
09/08/14PRA Health Sciences Files for Initial Public Offering
08 September 2014, Raleigh, N.C.  PRA Health Sciences, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering (“IPO”) of shares of its common stock by PRA Health Sciences and an affiliate of Kohlberg Kravis Roberts & Co. L.P. (the “Selling Stockholder”). The number of shares to be offered and the price range has not yet been determined.PRA Health Sciences intends to use... 
Printer Friendly Version